Earnings beat lifts Sumitomo Chemical 4005.T (JPX) to JPY 506.50 close 03 Feb 2026: outlook change

The market reacted sharply to Sumitomo Chemical Company, Limited Q3 results as 4005.T stock closed at JPY 506.50, up 7.77% on the day. The company reported an earnings surprise and strength in pharmaceuticals and semiconductor materials. Trading volume surged to 50,133,700.00 shares, well above the 50-day average of 10,644,737.00. This earnings-driven move reshapes near-term valuation talk for the JPX-listed chemicals heavyweight.

Earnings reaction and 4005.T stock movement

Sumitomo Chemical’s Q3 report triggered the price move, with the stock closing at JPY 506.50 after a intraday high of JPY 506.80. Trading volume jumped to 50,133,700.00, signaling institutional interest.

The earnings call and Q3 slides showed an EPS beat that supported the rally, and investors re-rated the company versus peers in Japan’s Basic Materials sector. Earnings transcript and market note confirm the market reaction.

Q3 results and segment drivers

Sumitomo Chemical reported stronger earnings across pharmaceuticals and semiconductor materials despite mixed top-line trends. EPS printed at 51.84, helping the stock trade at a PE of 8.83.

Management highlighted resilience in IT-related chemicals and health businesses, which offset softness in some petrochemical lines. The slide deck shows profit uplift even as revenue pressures remain. Company Q3 slides provide segment detail.

Valuation, cash flow and key metrics

At JPY 506.50, Sumitomo Chemical trades below many sector averages on multiples, with PE 8.83 and PB 0.78, and a market cap of JPY 749598379433.00. Free cash flow yield stands at 0.15 on the TTM metric.

Balance-sheet metrics show a debt to equity of 1.24 and a current ratio of 1.69, highlighting leverage that investors must monitor alongside strong cash generation metrics.

Meyka AI rates 4005.T with a score out of 100 and technical view

Meyka AI rates 4005.T with a score out of 100: 72.45 (Grade B+, suggestion BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Technically, momentum indicators are mixed. RSI is 54.17 and CCI reads 160.47, indicating short-term strength. Moving averages show the price above the 50-day (462.25) and 200-day (412.85) averages, suggesting a positive medium-term trend.

Analyst outlook, price targets and 4005.T stock forecast

Analyst coverage remains varied and no consensus price target is posted. Our realistic range is a conservative target near JPY 450.00, a base case JPY 520.00, and a bull case JPY 620.00, reflecting earnings momentum and cyclical recovery.

Meyka AI’s forecast model projects a monthly price of JPY 490.54 and a yearly level near JPY 287.76, reflecting model scenarios and macro sensitivity. Forecasts are model-based projections and not guarantees.

Risks and opportunities for 4005.T stock

Key upside drivers are ongoing strength in semiconductor materials and pharmaceuticals, plus higher cash flow conversion. Cost controls and product mix improvements could lift margins further.

Risks include cyclical weakness in petrochemicals, high leverage with debt to equity above sector norms, and sensitivity to commodity prices. Investors should weigh these against dividend yield of 2.62% and steady free cash flow.

Final Thoughts

Sumitomo Chemical (4005.T) closed the JPX session at JPY 506.50 on 03 Feb 2026 after a clear Q3 earnings beat. The surprise EPS of 51.84 and strong segment performance in pharmaceuticals and semiconductor materials triggered a volume spike to 50,133,700.00 shares and a re-rating versus basic materials peers. Meyka AI rates 4005.T with a score out of 100 at 72.45 (Grade B+, suggestion BUY), factoring in benchmark comparison, sector metrics, growth, and analyst signals. Meyka AI’s forecast model projects a monthly target of JPY 490.54, implying a modest downside of -3.13% from the current price, and a yearly scenario of JPY 287.76, implying -43.19%. These model outputs highlight sensitivity to cyclical shifts and commodity prices. Use the earnings beat as evidence of operational resilience, but balance it with leverage metrics and the company’s commodity exposure. For deeper data, see the Q3 transcript and slides linked above, and our Meyka stock page for 4005.T for live updates and charts.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.